Results were in line with expectations, and guidance was reaffirmed. The stock is likely to trade range-bound near-term. Monitor upcoming quarters for execution on volume recovery and margin trends.
Price Chart
Executive Summary
HCA Healthcare reported Q1 2026 results with revenue of $19.109 billion (4.3% YoY growth) and diluted EPS of $7.15, matching consensus. The company reaffirmed its full-year 2026 guidance and repurchased $1.571 billion in shares. Despite lower respiratory volumes, Medicaid supplemental program recognition offset impacts.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $19.109 billion, up 4.3% YoY
- Diluted EPS was $7.15, up 10.9% YoY and in line with consensus of $7.15
- Adjusted EBITDA increased 1.9% to $3.802 billion
- Company reaffirmed 2026 full-year guidance: EPS $29.10–$31.50, revenue $76.5–80.0 billion
- Repurchased 3.157 million shares for $1.571 billion during Q1
- Declared quarterly dividend of $0.78 per share
Financial Impact
Revenue increased 4.3% YoY to $19.109 billion; EPS of $7.15 matched consensus
Risk Factors
- Lower-than-expected patient volumes due to reduced respiratory activity
- Dependence on Medicaid supplemental payments for financial performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-174933 |
| Document: hca-20260424.htm | 0001193125-26-174933 |
| Document: 0001193125-26-174933-index-headers.html | 0001193125-26-174933 |
| Document: 0001193125-26-174933-index.html | 0001193125-26-174933 |
| Document: 0001193125-26-174933.txt | 0001193125-26-174933 |
| 8-K Data (Synthetic) | 0001193125-26-174933 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 24, 2026 10w ago | 8-K | $382.19 $429.19 | ▲ +12.30% | ▲ +8.67% | $426.69 (+11.64%) |
Jul 14, 2026 11w ago | 8-K | $363.60 $411.44 | ▼ −13.16% | ▼ −10.67% | $426.69 (−17.35%) |
Jun 18, 2026 15w ago | 8-K | $375.17 $385.74 | ▲ +2.82% | ▲ +2.28% | $426.69 (+13.73%) |
Apr 27, 2026 22w ago | 8-K | $431.48 $392.42 | ▼ −9.05% | ▼ −14.52% | $426.69 (−1.11%) |
Apr 27, 2026 22w ago | Court Ruling | $445.70 $392.48 | ▼ −11.94% | ▼ −16.87% | $426.69 (−4.26%) |
Apr 24, 2026 23w ago | 8-K | $432.55 $392.56 | ▼ −9.25% | ▼ −13.27% | $426.69 (−1.36%) |
Mar 13, 2026 29w ago | DEFA14A | $525.04 $496.74 | ▼ −5.39% | ▼ −9.17% | $426.69 (−18.73%) |
Feb 25, 2026 31w ago | 8-K | $525.78 $479.78 | ▼ −8.75% | ▼ −2.35% | $426.69 (−18.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access